CD9 and hepatocellular carcinoma: First, we evaluated the association of the fibulin‐4/CD9 ratio with liver fibrosis in the absence of HCC in seven healthy patients, 16 patients without liver disease (other diseases), 38 patients with CLD, 36 patients with Child–Pugh class A cirrhosis (without HCC), and 39 patients with Child–Pugh class B–C cirrhosis (without HCC).